Medtronic (MDT) closed the latest trading day at $90.07, indicating a +0.92% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. Meanwhile, the Dow experienced a rise of 0.69%, and the technology-dominated Nasdaq saw an increase of 0.8%.The medical device company's stock has climbed by 1.69% in the past month, exceeding the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97%.Analysts and investors alike will be keeping a close eye on ...

Medtronic (MDT) closed the latest trading day at $90.60, indicating a +0.01% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow gained 0.65%, and the Nasdaq, a tech-heavy index, added 0.26%.Shares of the medical device company witnessed a gain of 1.42% over the previous month, beating the performance of the Medical sector with its loss of 4.14% and underperforming the S&P 500's gain of 2%.Investors will be eagerly watching for th ...

Core Insights - Medtronic announced long-term data from the SPYRAL HTN-ON MED clinical trial, demonstrating significant reductions in blood pressure for patients undergoing radiofrequency renal denervation with the Symplicity™ Spyral system compared to sham patients at two years [1][2] - The company is expanding its clinical research efforts with the SPYRAL GEMINI pilot study to investigate multi-organ denervation and the GSR-DEFINE trial to include sites in the United States [3][5] Group 1: Clinical Trial Results - The SPYRAL HTN-ON MED trial showed a treatment difference in 24-hour ambulatory systolic blood pressure (ABPM) of -5.7 mmHg (RDN group: -12.1 mmHg vs. sham group: -7.0 mmHg, p=0.039) and in office-based systolic blood pressure (OSBP) of -8.7 mmHg (RDN group: -17.4 mmHg vs. sham group: -9.0 mmHg, p=0.0034) at two years [2] - No confirmed renal artery stenosis greater than 70% was reported in the Spyral group at the two-year mark, indicating long-term safety [2] Group 2: Future Clinical Programs - The SPYRAL GEMINI pilot study will explore the safety and efficacy of multi-organ denervation in patients with uncontrolled hypertension, both on and off medications [3][4] - The GSR-DEFINE trial is an extension of the Global SYMPLICITY Registry, aiming to enroll up to an additional 2,000 patients globally across 251 sites in 55 countries [5] Group 3: Company Positioning and Commitment - Medtronic emphasizes its unique position to explore blood pressure lowering through multi-organ denervation, supported by its intellectual property and the design of the Symplicity Spyral catheter [4] - The company is committed to evidence generation and innovation in interventional hypertension treatments, reinforcing its leadership in the field [6]

Core Insights - Medtronic has received FDA approval for the Affera Sphere-9 catheter, making it the first company to offer two PFA technologies for patients with atrial fibrillation (Afib) [1][2] - The Sphere-9 catheter integrates both mapping and ablation technologies, allowing for a single transeptal, zero-fluoroscopy, and zero-exchange workflow, enhancing procedural efficiency [2][3] - The Affera system aims to improve the safety, efficacy, and efficiency of Afib treatment, addressing the unmet needs of over 60 million people affected by this condition globally [3] Group 1: Product Details - The PulseSelect™ Pulsed Field Ablation System was FDA approved in December 2023, providing a single-shot solution for pulmonary vein isolation [1] - The Sphere-9 catheter features a 9mm lattice tip and can be used with an 8.5Fr sheath, offering flexibility in treatment options [1] - The Sphere-9 catheter allows for both pulsed field and radiofrequency energy delivery, fully integrated with the Affera Mapping and Ablation System [2] Group 2: Clinical Significance - The approval was based on positive results from the pivotal SPHERE Per-AF study, which compared the Sphere-9 catheter to conventional radiofrequency ablation methods [2] - The Affera Mapping and Ablation System received CE Mark in March 2023 and was approved in Australia in September 2024, indicating its international recognition [2] - Medtronic plans to evaluate the Sphere-9 catheter for treating ventricular tachycardia (VT) in an early feasibility study starting in October 2024 [2] Group 3: Company Commitment - Medtronic emphasizes its 75-year tradition of innovation aimed at addressing patient needs, with the Affera system representing a significant advancement in cardiovascular care [3] - The company is committed to ongoing innovation and expanding indications to improve patient outcomes in the field of cardiac health [3] - Medtronic's global team of over 95,000 employees is dedicated to developing technologies that transform healthcare and improve lives [5]

Core Viewpoint - Royal Philips and Medtronic Neurovascular have formed a strategic advocacy partnership to improve stroke care globally, emphasizing the importance of timely diagnosis and treatment to save lives and reduce long-term disability [1][4]. Group 1: Partnership and Advocacy - Philips and Medtronic Neurovascular have joined the World Stroke Organization Advocacy Coalition to collaborate with various stakeholders in addressing the global burden of stroke [2][6]. - The partnership aims to raise awareness about stroke symptoms and the necessity of immediate care, improve access to treatment, and leverage technology for integrated stroke care systems [3][5]. Group 2: Stroke Impact and Economic Burden - Stroke affects an estimated 12 million people globally each year, with direct and indirect costs estimated at around USD 900 billion annually, expected to nearly double in the next 25 years [3]. - The collaboration seeks to establish a global network of stroke care centers to provide comprehensive care from early diagnosis to rehabilitation [3]. Group 3: Upcoming Initiatives and Events - The collaboration will be showcased at the World Stroke Congress in Abu Dhabi, where both companies will host a Stroke Advocacy roundtable session [4]. - The partnership builds on previous joint efforts at significant events like the United Nations General Assembly, advocating for increased investments in stroke care infrastructure [4].

Medtronic (MDT) closed at $91.12 in the latest trading session, marking a +0.1% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.05% for the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.18%. Prior to today's trading, shares of the medical device company had gained 1.3% over the past month. This has outpaced the Medical sector's loss of 4.16% and lagged the S&P 500's gain of 2.76% in that time. Investors will be eagerly watching for the performa ...

Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revis ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios. Navigating this market can be a tricky endeavor. For one thing, there is plenty of interest rate uncertainty given the Fed's delicate balancing act of contr ...

Following a slump, shares of Medtronic (MDT) seem to have started to recuperate, possibly banking on a gradually improving investment and research scenario, thanks to the recent monetary policy easing. Closing Wednesday's trading session at $88.14, shares of this MedTech behemoth are currently trading near the 52-week high of $91.49. Fed's latest aggressive 50-bps rate cut, along with the high likelihood of another half a percentage point cut in the rest of 2024, as part of the central bank's gradual unwind ...

For Immediate ReleasesChicago, IL – October 9, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:JPMorgan Chase & Co. (JPM) , Medtronic plc (MDT) and Shopify Inc. (SHOP) and Perma-Pipe International Holdings, Inc. (PPIH) .Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for JPMorgan Chase, Med ...